vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and APTARGROUP, INC. (ATR). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $950.5M, roughly 1.0× Astrana Health, Inc.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 0.7%, a 7.0% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 13.5%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 2.6%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
ASTH vs ATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $962.7M |
| Net Profit | $6.6M | $74.3M |
| Gross Margin | — | — |
| Operating Margin | 1.9% | 11.0% |
| Net Margin | 0.7% | 7.7% |
| Revenue YoY | 42.9% | 13.5% |
| Net Profit YoY | 184.4% | -26.4% |
| EPS (diluted) | $0.12 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $962.7M | ||
| Q3 25 | $956.0M | $961.1M | ||
| Q2 25 | $654.8M | $966.0M | ||
| Q1 25 | $620.4M | $887.3M | ||
| Q4 24 | $665.2M | $848.1M | ||
| Q3 24 | $478.7M | $909.3M | ||
| Q2 24 | $486.3M | $910.1M | ||
| Q1 24 | $404.4M | $915.4M |
| Q4 25 | $6.6M | $74.3M | ||
| Q3 25 | $373.0K | $127.9M | ||
| Q2 25 | $9.4M | $111.7M | ||
| Q1 25 | $6.7M | $78.8M | ||
| Q4 24 | $-7.8M | $100.9M | ||
| Q3 24 | $16.1M | $100.0M | ||
| Q2 24 | $19.2M | $90.5M | ||
| Q1 24 | $14.8M | $83.1M |
| Q4 25 | 1.9% | 11.0% | ||
| Q3 25 | 2.0% | 14.2% | ||
| Q2 25 | 3.1% | 14.9% | ||
| Q1 25 | 3.3% | 12.8% | ||
| Q4 24 | 0.1% | 14.2% | ||
| Q3 24 | 5.9% | 15.2% | ||
| Q2 24 | 6.2% | 13.8% | ||
| Q1 24 | 7.5% | 12.2% |
| Q4 25 | 0.7% | 7.7% | ||
| Q3 25 | 0.0% | 13.3% | ||
| Q2 25 | 1.4% | 11.6% | ||
| Q1 25 | 1.1% | 8.9% | ||
| Q4 24 | -1.2% | 11.9% | ||
| Q3 24 | 3.4% | 11.0% | ||
| Q2 24 | 3.9% | 9.9% | ||
| Q1 24 | 3.7% | 9.1% |
| Q4 25 | $0.12 | $1.13 | ||
| Q3 25 | $0.01 | $1.92 | ||
| Q2 25 | $0.19 | $1.67 | ||
| Q1 25 | $0.14 | $1.17 | ||
| Q4 24 | $-0.14 | $1.48 | ||
| Q3 24 | $0.33 | $1.48 | ||
| Q2 24 | $0.40 | $1.34 | ||
| Q1 24 | $0.31 | $1.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $409.5M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $779.3M | $2.7B |
| Total Assets | $2.2B | $5.3B |
| Debt / EquityLower = less leverage | — | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | $409.5M | ||
| Q3 25 | $463.4M | $264.8M | ||
| Q2 25 | $342.1M | $169.8M | ||
| Q1 25 | $260.9M | $136.8M | ||
| Q4 24 | $290.8M | $226.2M | ||
| Q3 24 | $350.3M | $327.9M | ||
| Q2 24 | $327.7M | $223.9M | ||
| Q1 24 | $337.3M | $201.1M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $546.0M | ||
| Q2 25 | — | $535.1M | ||
| Q1 25 | — | $561.2M | ||
| Q4 24 | — | $688.1M | ||
| Q3 24 | — | $822.7M | ||
| Q2 24 | — | $681.5M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | $779.3M | $2.7B | ||
| Q3 25 | $775.5M | $2.8B | ||
| Q2 25 | $765.5M | $2.7B | ||
| Q1 25 | $745.4M | $2.5B | ||
| Q4 24 | $712.7M | $2.5B | ||
| Q3 24 | $704.6M | $2.5B | ||
| Q2 24 | $678.9M | $2.4B | ||
| Q1 24 | $653.5M | $2.3B |
| Q4 25 | $2.2B | $5.3B | ||
| Q3 25 | $2.2B | $5.1B | ||
| Q2 25 | $1.4B | $4.9B | ||
| Q1 25 | $1.3B | $4.5B | ||
| Q4 24 | $1.4B | $4.4B | ||
| Q3 24 | $1.3B | $4.6B | ||
| Q2 24 | $1.3B | $4.5B | ||
| Q1 24 | $1.2B | $4.4B |
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.28× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $183.7M |
| Free Cash FlowOCF − Capex | $-6.0M | $96.9M |
| FCF MarginFCF / Revenue | -0.6% | 10.1% |
| Capex IntensityCapex / Revenue | 0.3% | 9.0% |
| Cash ConversionOCF / Net Profit | -0.44× | 2.47× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $299.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $183.7M | ||
| Q3 25 | $10.0M | $177.6M | ||
| Q2 25 | $90.9M | $126.0M | ||
| Q1 25 | $16.6M | $82.7M | ||
| Q4 24 | $-10.9M | $178.2M | ||
| Q3 24 | $34.0M | $229.3M | ||
| Q2 24 | $23.2M | $143.6M | ||
| Q1 24 | $6.0M | $92.3M |
| Q4 25 | $-6.0M | $96.9M | ||
| Q3 25 | $7.4M | $114.3M | ||
| Q2 25 | $89.5M | $62.5M | ||
| Q1 25 | $13.6M | $25.9M | ||
| Q4 24 | $-13.5M | $112.2M | ||
| Q3 24 | $31.7M | $162.7M | ||
| Q2 24 | $20.4M | $75.4M | ||
| Q1 24 | $5.6M | $16.7M |
| Q4 25 | -0.6% | 10.1% | ||
| Q3 25 | 0.8% | 11.9% | ||
| Q2 25 | 13.7% | 6.5% | ||
| Q1 25 | 2.2% | 2.9% | ||
| Q4 24 | -2.0% | 13.2% | ||
| Q3 24 | 6.6% | 17.9% | ||
| Q2 24 | 4.2% | 8.3% | ||
| Q1 24 | 1.4% | 1.8% |
| Q4 25 | 0.3% | 9.0% | ||
| Q3 25 | 0.3% | 6.6% | ||
| Q2 25 | 0.2% | 6.6% | ||
| Q1 25 | 0.5% | 6.4% | ||
| Q4 24 | 0.4% | 7.8% | ||
| Q3 24 | 0.5% | 7.3% | ||
| Q2 24 | 0.6% | 7.5% | ||
| Q1 24 | 0.1% | 8.3% |
| Q4 25 | -0.44× | 2.47× | ||
| Q3 25 | 26.69× | 1.39× | ||
| Q2 25 | 9.65× | 1.13× | ||
| Q1 25 | 2.48× | 1.05× | ||
| Q4 24 | — | 1.77× | ||
| Q3 24 | 2.11× | 2.29× | ||
| Q2 24 | 1.21× | 1.59× | ||
| Q1 24 | 0.40× | 1.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
